Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glibenclamide in Kir6.2/SUR1 Neonatal Diabetes
NCT00610038Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2006
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of glibenclamide in Permanent neonatal diabetes mellitus (PNDM), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Continuous capillary glycaemia at 3 days and Insulin secretion under insulin and sulfonylureas. Started Jul 2006; status: completed.
02
Drugs
glibenclamide
03
Conditions
Permanent neonatal diabetes mellitus (PNDM)
Beyond the preview
Go deeper on NCT00610038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00610038.